Skip to content
207.878.2770mail@immucell.com
Immucell
Immediate Immunity™
Immucell
  • About ImmuCell
    • About ImmuCell
    • Our Purpose
    • Management and Directors
    • Career Opportunities
    • Contact Us
  • First Defense
    • First Defense® Tri-Shield and First Defense for Scours
    • Testimonials
  • Re-Tain
    • Re-Tain™ for Mastitis
    • CMT for Mastitis
  • Sales & Distributors
  • Resources
  • News
  • Investors
  • About ImmuCell
    • About ImmuCell
    • Our Purpose
    • Management and Directors
    • Career Opportunities
    • Contact Us
  • First Defense
    • First Defense® Tri-Shield and First Defense for Scours
    • Testimonials
  • Re-Tain
    • Re-Tain™ for Mastitis
    • CMT for Mastitis
  • Sales & Distributors
  • Resources
  • News
  • Investors
STOCK QUOTE
PRESS RELEASES

Recent News | 2018 | 2017 | 2016 | 2015 | 2014

SEC FILINGS
SEC FIlings

XBRL Documents

Annual Report and Proxy
CORPORATE GOVERNANCE
ICCC Code of Conduct

Charter and Powers of the Audit Committee

Nominating Committee Charter

Management & Directors

2015 Press Releases

2019  |  2018  |  2017  |  2016  |  2015  |  2014

12-22-2015 ImmuCell Enters into New Contract with Norbrook

11-12-2015 ImmuCell Announces Results for Third Quarter of 2015

11-5-2015 ImmuCell to Announce Third Quarter 2015 Financial Results

8-13-2015 ImmuCell Announces Results for Second Quarter of 2015

8-6-2015 ImmuCell to Announce Second Quarter 2015 Financial Results

7-8-2015 ImmuCell Corp. Increases Sales Guidance for Second Quarter of 2015

5-12-2015 ImmuCell Announces Results for First Quarter of 2015

5-6-2015 ImmuCell to Announce First Quarter 2015 Financial Results

4-15-2015 ImmuCell Board of Directors Amends Its Common Stock Rights Plan

4-14-2015 ImmuCell Announces New Bacteriocin Collaboration With The University of Massachusetts Amherst

2-25-2015 ImmuCell Reports Results from Rotavirus Pivotal Effectiveness Study

2-12-2015 Bobbi Jo Brockmann promoted to Vice President of Sales and Marketing

2-11-2015 ImmuCell Announces Financial Results for 2014

2-4-2015 ImmuCell to Announce 2014 Full Year and Fourth Quarter Financial Results

COMPANY CONTACT

Michael F. Brigham
President & CEO
mail@immucell.com
207.878.2770

INVESTOR CONTACT
Lytham Partners, LLC
iccc@lythampartners.com
602.889.9700
Contact Us

56 Evergreen Drive
Portland, ME 04103

Office: 207.878.2770
Sales: 1.800.IMMUCELL
mail@immucell.com

NASDAQ: ICCC

Privacy Policy

Terms of Use

Recent News

11-11-19 ImmuCell Announces Unaudited Financial Results for Third Quarter of 2019

11-05-19 ImmuCell to Announce Unaudited Financial Results for Third Quarter of 2019

09-17-19 ImmuCell Enters into Lease Agreement for a Facility to Expand First Defense® Production Capacity

09-11-19 ImmuCell Announces an Agreement Covering the Formulation and Aseptic Filling of Syringes for Re-Tain™

Follow Us

Find us on:

FacebookYouTube
Copyright © 2019 ImmuCell Corporation
  • Home
  • About ImmuCell
  • First Defense
  • Re-Tain
  • Sales & Distributors
  • Resources
  • News
  • Investors
  • Contact Us
Footer Menu
Go to Top